Table 3

Clinical studies, antimicrobial therapies, and outcomes for patients infected with MβL-producing K. pneumoniae

ReferenceCountry (yr of publication)Study designNo. of patients with indicated type of infectionType of MBL (no. of isolates)Treatment (no. of patients)Outcome (no. of successes/no. of failures)
121 Greece (2004)Case reports4 (2 BSIs, 1 case of mediastinitis, 1 bone infection)VIM-1 (4)Colistin (1)1/0
86 Greece (2008)Tigecycline (1)1/0
56 Spain (2008)Tigecycline-colistin (2)1/1
223 Ireland (2010)
269 Taiwan (2001)Case series3 BSIsIMP-8 (3)Carbapenem (3)1/2
143 Taiwan (2004)Case series3 (2 pneumonias, 1 BSI)IMP-type enzyme (3)Carbapenem (1)1/0
Carbapenem-aminoglycoside (2)2/0
240 Greece (2008)Case series17 (14 BSIs, 3 pneumonias)VIM-1 (17)Colistin (6)6/0
Tigecycline (1)0/1
Colistin-aminoglycoside (2)2/0
Colistin doxycycline (1)0/1
Carbapenem-colistin (6)5/1
Carbapenem-aminoglycoside-doxycycline (1)1/0
175 Greece (2010)Case-control study18 BSIsVIM-1 (17)Colistin (10)6/4
VIM-type enzyme (1)Colistin-aminoglycoside (8)4/4
64 Greece (2007)Retrospective study28 BSIsVIM-1 (28)Carbapenem (8)7/1
Colistin (4)0/4
Aminoglycoside (3)2/1
Carbapenem-aminoglycoside (6)6/0
Carbapenem-colistin (1)1/0
Aztreonam-aminoglycoside (2)1/1
No active drug (4)2/2
67 Greece (2009)Prospective observational study67 BSIsVIM-1 (67)Carbapenem (14)11/3
Carbapenem-colistin (8)8/0
Carbapenem-aminoglycoside (4)3/1
Colistin (15)11/4
Aminoglycoside (8)5/3
No active drug (18)13/5